ENTA

Gardiner Nathaniel S.

Known title: Sr. VP & General CounselCIK: 0001607643

Associated companies

AI Market Commentary

AI-generatedAll commentary →

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

September 26, 2026

HC Wainwright Maintains $20 Target for Enanta. HC Wainwright reiterated its stance on Enanta Pharmaceuticals, keeping a price target of $20. This view aligns with the broader analyst consensus, where the average target across six analysts is $21.83. The stock is currently trading near its 52-week low, with recent technical signals indicating support at $13.25.

this person other insiders at ENTA

Transaction History

ENTA▲ Buy$47K
ENTA▲ Buy$0
ENTA▼ Sell$12K
ENTA▼ Sell$23K
ENTA▼ Sell$15K
ENTA▲ Buy$200K
ENTA▼ Sell$355K
ENTA▲ Buy$0
ENTA▲ Buy$0
ENTA▼ Sell$47K
ENTA▲ Buy$0
ENTA▲ Buy$0
ENTA▲ Buy$0
ENTA▼ Sell$60K
ENTA▼ Sell$49K
ENTA▲ Buy$0

We use analytics to understand how market-wall is used. No personal data is sold.